Cascade has developed propriety technology
that has the power to convert anticancer
compounds into targeted pro drugs in its mission
to more effectively treat cancer. The company
owns and is continuing to develop a
“platform technology” which results in an ability to
develop drugs efficiently across multiple classes of
anticancer compounds in particular those with a
low therapeutic index.
Cascade is leveraging a worldwide network
of experts bring contracted expertise into
the projects in an effort to control costs and
improve the preclinical outcome for its
compounds. We actively seek partnering relationships to maximize shareholder value.